The field of nanomedicine is constantly expanding. Since the first work dated in 1999, almost 28 thousand articles have been published, and more and more are published every year: just think that only in the last five years 20,855 have come out (source PUBMED) including original research and reviews. The goal of this review is to present the current knowledge about nanomedicine in Alzheimer’s disease, a widespread neurodegenerative disorder in the over 60 population that deeply affects memory and cognition. Thus, after a brief introduction on the pathology and on the state-of-the-art research for NPs passing the BBB, special attention is placed to new targets that can enter the interest of nanoparticle designers and to new promising therapies. The authors performed a literature review limited to the last three years (2017–2020) of available studies with the intention to present only novel formulations or approaches where at least in vitro studies have been performed. This choice was made because, while limiting the sector to nanotechnology applied to Alzheimer, an organic census of all the relevant news is difficult to obtain.

Binda, A., Murano, C., Rivolta, I. (2020). Innovative therapies and nanomedicine applications for the treatment of alzheimer’s disease: A state-of-the-art (2017–2020). INTERNATIONAL JOURNAL OF NANOMEDICINE, 15, 6113-6135 [10.2147/IJN.S231480].

Innovative therapies and nanomedicine applications for the treatment of alzheimer’s disease: A state-of-the-art (2017–2020)

Binda, A;Murano, C;Rivolta, I
2020

Abstract

The field of nanomedicine is constantly expanding. Since the first work dated in 1999, almost 28 thousand articles have been published, and more and more are published every year: just think that only in the last five years 20,855 have come out (source PUBMED) including original research and reviews. The goal of this review is to present the current knowledge about nanomedicine in Alzheimer’s disease, a widespread neurodegenerative disorder in the over 60 population that deeply affects memory and cognition. Thus, after a brief introduction on the pathology and on the state-of-the-art research for NPs passing the BBB, special attention is placed to new targets that can enter the interest of nanoparticle designers and to new promising therapies. The authors performed a literature review limited to the last three years (2017–2020) of available studies with the intention to present only novel formulations or approaches where at least in vitro studies have been performed. This choice was made because, while limiting the sector to nanotechnology applied to Alzheimer, an organic census of all the relevant news is difficult to obtain.
Articolo in rivista - Review Essay
Alzheimer’s disease; Green synthesis; Intranasal route; Nanomedicine; Nanoparticles; Nutraceutical; Stem cells; Therapy;
Alzheimer’s disease, therapy, nanomedicine, nanoparticles, nutraceutical, intranasal route, green synthesis, stem cells
English
2020
15
6113
6135
none
Binda, A., Murano, C., Rivolta, I. (2020). Innovative therapies and nanomedicine applications for the treatment of alzheimer’s disease: A state-of-the-art (2017–2020). INTERNATIONAL JOURNAL OF NANOMEDICINE, 15, 6113-6135 [10.2147/IJN.S231480].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/282292
Citazioni
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 27
Social impact